ArticleCornea2018
Corneal Collagen Cross-Linking With Riboflavin and Ultraviolet A Light for Pediatric Keratoconus: Ten-Year Results.
Article in Cornea, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed.
- Three-year results of accelerated transepithelial cross-linking (30 mW/cmBMJ open ophthalmology · 2022Trial
- The Science and Clinical Evolution of Corneal Cross-Linking: Mechanism of Action, Ultra-Structural Changes, Clinical Indications, and Emerging Treatment Strategies.Ophthalmology and therapy · 2026Review
- Paediatric Keratoconus: An ERN-EYE Clinical Consensus Statement on Diagnosis, Treatment and Follow-Up Care.Ophthalmology and therapy · 2026Review
- Biomechanical and Tomographic Outcomes in Pediatric Keratoconus Treated with Conventional Epithelium-Off Corneal Collagen Cross-Linking.Medicina (Kaunas, Lithuania) · 2026Observational
- Evaluation of 60 months long-term results of accelerated corneal cross-linking treatment in pediatric keratoconus patients with new progression indices.Japanese journal of ophthalmology · 2026Observational
- Anti-inflammatory and dry eye benefits of accelerated epi-off corneal cross-linking in pediatric keratoconus with allergic ocular surface disease and elevated MMP-9.Eye and vision (London, England) · 2026Article
- Article
- Long-term outcomes after high-energy accelerated pulsed corneal cross-linking (15 mW/cmInternational ophthalmology · 2025Article
- Six-Month Outcomes of Accelerated Corneal Cross-Linking with a Total Dose of 7.2 J/cm2 Using Dextran-Free Riboflavin.Korean journal of ophthalmology : KJO · 2025Article
- Comparison of the 1-year efficacy of epithelium-off and transepithelial accelerated corneal collagen crosslinking in adolescent keratoconus.Eye (London, England) · 2025Observational
- Keratometry Changes Between Year Seven and Twelve After Corneal Crosslinking in Patients with Keratoconus.Journal of clinical medicine · 2025Article
- Understanding Keratoconus in Down Syndrome: From Etiology to Management - A Narrative Review.Clinical ophthalmology (Auckland, N.Z.) · 2025Review
- Corneal surface changes after stromal lenticule addition keratoplasty combined with cross-linking for severe keratoconus.International journal of ophthalmology · 2025Article
- Cost-Effectiveness of Corneal Collagen Crosslinking for Progressive Keratoconus: A Brazilian Unified Health System Perspective.International journal of environmental research and public health · 2024Article
- Epi-off riboflavin with vitamin E TPGS (Ribocross®) cross-linking: one-year outcome.International ophthalmology · 2024Article
- Keratoconus.Nature reviews. Disease primers · 2024Article
- Outcomes of accelerated corneal cross-linking for pediatric and adult keratoconus: a comparative study.International ophthalmology · 2024Article
- Topography-guided photorefractive keratectomy combined with accelerated corneal collagen cross-linking versus cross-linking alone for progressive keratoconus: a long-term prospective cohort study.Frontiers in medicine · 2024Article
- Corneal crosslinking via the Dresden protocol versus the accelerated approach in pediatric patients - a retrospective comparative study.Arquivos brasileiros de oftalmologia · 2024Article
- Keratoconus: imaging modalities and management.Medical hypothesis, discovery & innovation ophthalmology journal · 2024Review
10 more citing papers are in PubMed but not listed here.
Corrections and comments
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo assess the 10-year follow-up efficacy and safety of riboflavin ultraviolet A-induced cross-linking (CXL) in a population of pediatric patients aged 18 years and younger with progressive keratoconus (KC).
methodsThe prospective longitudinal cohort study included 62 eyes of 47 keratoconic patients undergoing epithelium-off CXL who completed 10-year follow-up. The surgical procedure was performed in all patients according to the Siena (Dresden modified) protocol. Evaluation included uncorrected distance visual acuity, corrected distance visual acuity, Scheimpflug corneal tomography, and optical coherence tomography demarcation line measurement. Follow-up measurements taken up to 10 years after treatment were compared with baseline values, and statistical analysis was performed using a 2-tailed paired sample Student t test.
resultsUncorrected distance visual acuity and corrected distance visual acuity improved from 0.45 to 0.23 logarithm of the minimum angle resolution (P = 0.0001) and from 0.14 to 0.1 logarithm of the minimum angle resolution (P = 0.019). KC stability was recorded after 10 years of follow-up in nearly 80% of the patients. The overall 10-year follow-up progression rate was 24% including 13 eyes of 9 patients with Kmax progression over 1 diopter and 2 eyes of 2 patients who underwent corneal grafting.
conclusionsThe study demonstrates the ability of CXL to slow down KC progression in pediatric patients, improving functional performance. Long-term stability may be correlated with CXL-induced delay in corneal collagen turnover and with spontaneous age-related KC stabilization. A 24% regression rate could be contemplated in the patients who were aged 15 years and younger at the time of inclusion in the treatment protocol.
Indexed as
Identifiers
29319598What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.